Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma

BackgroundThere is no neoadjuvant immunotherapy for early-stage oral cancer patients. We report a single-arm, open-label, pilot clinical trial assessing the efficacy and safety of topical toll-like receptor-7 (TLR-7) agonist, imiquimod, utilized in a neoadjuvant setting in early-stage oral squamous...

Full description

Saved in:
Bibliographic Details
Main Authors: Angela J. Yoon, Richard D. Carvajal, Evan M. Graboyes, John M. Kaczmar, William G. Albergotti, Alexandra E. Kejner, Scott H. Troob, Elizabeth Philipone, Jean-Sebastien Anoma, Kent E. Armeson, Elizabeth G. Hill, Mary S. Richardson, Tina R. Woods, Bhishamjit S. Chera, Farzad Nourollah-Zadeh, Byung J. Lee, Subramanya Pandruvada, Antonis Kourtidis, Christina Kingsley, Elizabeth C. O’Quinn, Stephanie Mills, Victoria C. Jordan, Mike Spencer, Danielle Fails, Trevor D. McKee, Mark Zaidi, Alan Brisendine, Shane Horn, Shikhar Mehrotra, Besim Ogretmen, Jason G. Newman
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
oral cancer
neoadjuvant clinical trial
toll-like 7 receptor agonist
imiquimod
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530262/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530262/full

Similar Items